Cardiovascular Consequences of Autoimmune Rheumatic Diseases

(E-pub Ahead of Print)

Author(s): Fabiola Atzeni*, Valeria Nucera, Elisabetta Gerratana, Alessia Fiorenza, Luigi Gianturco, Marco Corda, Piercarlo Sarzi-Puttini.

Journal Name: Current Vascular Pharmacology

Become EABM
Become Reviewer


The increased risk of cardiovascular disease (CVD) among patients with autoimmune rheumatic dis-eases such as rheumatoid arthritis, spondyloarthritis and systemic lupus erythematosus has been exten-sively documented. Sub-clinical atherosclerosis can be assessed using various non-invasive imaging techniques. However, the mechanisms underlying the greater risk of atherosclerotic CVD in patients with autoimmune rheumatic diseases are not fully known, although they seem to include chronic low-grade systemic inflammation leading to prolonged endothelial activation, accompanied by a pro-thrombotic/pro-coagulant and autoantibody state. Furthermore, sub-clinical atherosclerosis is also in-fluenced by other traditional risk factors for CVD. Including the individual components of the meta-bolic syndrome (MetS: obesity, impaired glucose metabolism, dyslipidemia and high blood pressure), the degree of which is higher in these patients than in controls. The aim of this narrative review is to discuss the CV manifestations and risk factors involved in the increased risk of CVD among patients with autoimmune rheumatic diseases.

Keywords: Cardiovascular involvement, systemic lupus erythematosus, rheumatoid arthritis, spondyloarthritis

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1570161118666200127142936
Price: $95

Article Metrics

PDF: 1